The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
Dunne E, Fick C, Isbell J, Chaft J, Altorki N, Park B, Spicer J, Forde P, Gomez D, Iyengar P, Harpole D, Stinchcombe T, Liberman M, Bott M, Adusumilli P, Huang J, Rocco G, Jones D. The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer. The Annals Of Thoracic Surgery 2024, 118: 119-129. PMID: 38316378, PMCID: PMC11194155, DOI: 10.1016/j.athoracsur.2024.01.024.Peer-Reviewed Original ResearchResected non-small cell lung cancerNon-small cell lung cancerAdvanced non-small cell lung cancerImmune checkpoint inhibitorsPhase III trialsCell lung cancerICI therapyPerioperative immunotherapyIII trialsLocally advanced non-small cell lung cancerTreatment of resectable non-small cell lung cancerLung cancerLong-term survival of patientsPathologic complete response rateUnited States Food and Drug Administration approvalRandomized phase III trialClinical trials of immunotherapyTreatment of non-small cell lung cancerFood and Drug Administration approvalImpairs surgical outcomesComplete response rateSignificant survival benefitTrials of immunotherapySurvival of patientsDrug Administration approval